Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1984 1
1996 1
2001 1
2002 2
2010 1
2011 1
2014 1
2020 7
2021 13
2022 20
2023 14
2024 12
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
[Prevention of preeclampsia and its complications].
Allard M, Grosch S, Jouret F, Masson V, Surinder T, Masset C. Allard M, et al. Among authors: masset c. Rev Med Liege. 2024 Jun;79(5-6):448-454. Rev Med Liege. 2024. PMID: 38869138 Free article. Review. French.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France.
Maanaoui M, Lenain R, Foucher Y, Buron F, Blancho G, Antoine C, Caillard S, Kessler L, Le Quintrec M, Villard O, Anglicheau D, Büchler M, Brodin-Sartorius A, Frimat L, Malvezzi P, Lablanche S, Badet L, Esposito L, Chetboun M, Hamroun A, Kerr-Conte J, Berney T, Vantyghem MC, Hazzan M, Pattou F; TREPID-ABM study group. Maanaoui M, et al. Lancet Diabetes Endocrinol. 2024 Oct;12(10):716-724. doi: 10.1016/S2213-8587(24)00241-9. Epub 2024 Sep 6. Lancet Diabetes Endocrinol. 2024. PMID: 39250921
2024: A Year in Review.
Berney T, Bellini MI, Benning L, Bestard O, Masset C, Moeckli B, Pascale MM, Pilat N, Sabatino M, Schneeberger S. Berney T, et al. Among authors: masset c. Transpl Int. 2025 Jan 14;37:14243. doi: 10.3389/ti.2024.14243. eCollection 2024. Transpl Int. 2025. PMID: 39877477 Free PMC article. No abstract available.
Virus-Associated Nephropathies: A Narrative Review.
Masset C, Le Turnier P, Bressollette-Bodin C, Renaudin K, Raffi F, Dantal J. Masset C, et al. Int J Mol Sci. 2022 Oct 10;23(19):12014. doi: 10.3390/ijms231912014. Int J Mol Sci. 2022. PMID: 36233315 Free PMC article. Review.
The concept of immunothrombosis in pancreas transplantation.
Masset C, Drillaud N, Ternisien C, Degauque N, Gerard N, Bruneau S, Branchereau J, Blancho G, Mesnard B, Brouard S, Giral M, Cantarovich D, Dantal J; TREPID Group. Masset C, et al. Am J Transplant. 2025 Apr;25(4):650-668. doi: 10.1016/j.ajt.2024.11.025. Epub 2024 Dec 19. Am J Transplant. 2025. PMID: 39709128 Review.
Questions about the BEST-Fluids trial.
Masset C, Chapelet A, Dumont R, Ville S, Garandeau C, Houzet A, Kervella D, Dantal J, Blancho G, Cantarovich D, Giral M, Figueres L; Nantes DIVAT Consortium. Masset C, et al. Lancet. 2024 Mar 9;403(10430):909-910. doi: 10.1016/S0140-6736(23)02682-X. Lancet. 2024. PMID: 38460985 No abstract available.
Art in the ward: nephrology picture.
Drapeau L, David A, Karam G, Masset C. Drapeau L, et al. Among authors: masset c. J Nephrol. 2021 Dec;34(6):2099-2100. doi: 10.1007/s40620-021-01008-y. Epub 2021 Apr 1. J Nephrol. 2021. PMID: 33792835 No abstract available.
78 results